Hypertension (HTN) is a preventable condition with complex etiology. Neurogenic origins of HTN such as aberrant signaling in the paraventricular nucleus (PVN) of the hypothalamus remain a high priority for therapeutic interventions, as most anti‐HTN treatments remain ineffective in a significant portion of patients. Discerning the molecular mechanisms underlying neurogenic HTN is critical for understanding how an overactive sympathetic drive contributes to high blood pressure. We generated a novel bone marrow‐specific adrenergic beta 1 and beta 2 knockout mouse chimera (AdrB1.B2 KO mouse) to study how sympathetic drive to the bone, or lack thereof, affects the molecular responses in the PVN. These mice have previously been characterized by dampened systemic immune responses and decreased blood pressure during the active period. Here, loss of sympathetic drive in the AdrB1.B2 KO chimera lead to an overwhelming suppression of transcriptional networks in the PVN that included leukocyte cell adhesion and migration as well as lymphocyte activation and adhesion, and T cell‐ activation and recruitment. Furthermore, transcriptome networks associated with astroglia, microglial, and neuronal function were suppressed in the PVN of AdrB1.B2 KO chimera. Transcriptional networks related to IL‐17a signaling and the renin‐angiotensin system related genes were also suppressed in the PVN of the AdrB1.B2 KO chimera. Using computational predictive tools, we identified a number of miRNAs expected to regulate global transcriptome responses in the PVN. These included miR‐27b3p, miR‐150, miR‐223, and miR‐326, some of which have been implicated in HTN. In addition, using qPCR, we observed a downregulation in the relative expression of miR‐150, miR‐205, miR‐223, miR‐375, miR‐499a, and miR‐27b3p in the PVN of AdrB1.B2 KO chimera, thus in part confirming the results of computational predictive tools. This study identifies novel molecular mechanisms involved in neural‐immune interactions that underlie neurogenic HTN and elucidate new pathways for therapeutic intervention.Support or Funding InformationSupported by AHA grant 14SDG18300010 to JZ and NIH R21AT010192 Award AWD05242 P0104932 to CJM and JZ.
Read full abstract